This study aims to assess the safety and efficacy of GDHT using the non-invasive Starling™ SV System in elective neurosurgery. The tested group of patients (n=70) will be compared with a control group (n=70), where hemodynamic management will be guided by standard vital signs monitoring.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with acute kidney Injury
Timeframe: 28 days
Number of participants with acute Respiratory Distress Syndrome (ARDS)
Timeframe: 28 days
Number of participants with arrhythmia
Timeframe: 28 days
Number of participants with cardiac arrest
Timeframe: 28 days
Number of participants with cardiogenic pulmonary oedema
Timeframe: 28 days
Number of participants with deep vein thrombosis (DVT)
Timeframe: 28 days
Number of participants with pulmonary embolism (PE)
Timeframe: 28 days
Number of participants with gastrointestinal bleed
Timeframe: 28 days
Number of participants with infection, source uncertain
Timeframe: 28 days
Number of participants with laboratory confirmed bloodstream infection
Timeframe: 28 days
Number of participants with myocardial infarction
Timeframe: 28 days
Number of participants with pneumonia
Timeframe: 28 days
Number of participants with paralytic ileus
Timeframe: 28 days
Number of participants with postoperative haemorrhage
Timeframe: 28 days
Number of participants with stroke
Timeframe: 28 days
Number of participants with brain oedema
Timeframe: 28 days
Number of participants with surgical site infection (superficial)
Timeframe: 28 days
Number of participants with surgical site infection (deep)
Timeframe: 28 days
Number of participants with surgical site infection (organ/space)
Timeframe: 28 days
Number of participants with urinary tract infection
Timeframe: 28 days